Fosun Pharma

Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows

A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?

China Speed: Two COVID-19 Vaccines Recognized by WHO

As the second blow of the pandemic comes near the sight, China's newly-developed vaccines have been approved by the World Health Organization and available at an affordable price.

Fosun Pharma’s COVID-19 Vaccine Starts Clinical Phase, Approved by Chinese NMPA

The giant Chinese pharmaceutical’s preventive vaccine is entering a new phase, bringing it closer to future commercialization.

China’s Healthcare ETF: The Next Limelight

Amid the COVID-19 pandemic, the Chinese Shenzhen stock market was the only market with a positive growth rate (in Q1 2020). In the meantime, China’s healthcare industry has got more of a spotlight on the global stage.

First Come, First Cured: Chinese Drugmakers Race for COVID-19 Solutions

The first outbreak also generates the earliest responders. CanSino Biologics (06185: HKSE) is leaping ahead of all other 69 vaccine candidates to advance into the Phase 2 clinical trial.